Swarm Oncology Ltd., a biotechnology company, has partnered with Cellex Cell Professionals GmbH, a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy (CGT) manufacturing, to accelerate the development and manufacturing of its T cell therapies for advanced solid cancers.

Through this partnership, Cellex will supply cellular starting material and oversee process transfer, GMP manufacturing, and quality control. Additionally, Cellex will provide regulatory compliance support and specialized infrastructure to accelerate Swarm’s therapies toward clinical trials in 2026. The partnership aims to accelerate clinical timelines, reduce manufacturing bottlenecks, and enhance scalability, to bring Swarm’s innovative T cell therapies to solid tumor patients in need.

Martin Olin, CEO of Swarm, said, “Swarm’s mission is to transform immunotherapy by overcoming its limitations and driving solid cancers into long-term remission. With Cellex’s deep expertise in cell collection, therapy manufacturing, and regulatory compliance, we can ensure a seamless, high-quality manufacturing process and advance clinical development, bringing life-changing treatments to patients with the reliability and scale they need.”

“We are excited to contribute to Swarm’s mission to drive innovation in solid cancer treatment,” added Prof. Dr. Gerhard Ehninger, Cellex’s CEO. “With our modern facilities and over 10 years of experience in T cell therapy manufacturing, we are well-positioned to help bring these transformative therapies to the clinic faster and more efficiently.”